Quadruple therapy with immunotherapy and chemotherapy as first-line conversion treatment for unresectable advanced gastric adenocarcinoma: A case report

doi:10.4251/wjgo.v17.i4.102258

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (55)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-4) series.

Item

Count

PDF

HTML

Figures (1-4)

Sum=53

Apr 15, 2025 (publication date) through Mar 25, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Gastrointest Oncol. Apr 15, 2025; 17(4): 102258
Published online Apr 15, 2025. doi: 10.4251/wjgo.v17.i4.102258

Quadruple therapy with immunotherapy and chemotherapy as first-line conversion treatment for unresectable advanced gastric adenocarcinoma: A case report

Xiao-Yu Du, Ren-Jie Xia, Li-Wen Shen, Jian-Guo Ma, Wei-Qing Yao, Wei Xu, Zhi-Peng Lin, Liang-Bin Ma, Guo-Qiang Niu, Rui-Fang Fan, Shu-Mei Xu, Long Yan

Xiao-Yu Du, Ren-Jie Xia, Jian-Guo Ma, Wei-Qing Yao, Wei Xu, Zhi-Peng Lin, Liang-Bin Ma, Guo-Qiang Niu, Rui-Fang Fan, Shu-Mei Xu, Long Yan, Department of Hepatobiliary Surgery and General Surgery, The 940^th Hospital of Joint Logistic Support Force of Chinese People’s Liberation Army, Lanzhou 730050, Gansu Province, China

Xiao-Yu Du, Ren-Jie Xia, Wei-Qing Yao, Department of Medicine, Northwest Minzu University, Lanzhou 730050, Gansu Province, China

Li-Wen Shen, Department of Medical Support Center, The 940th Hospital of Joint Logistic Support Force of Chinese People’s Liberation Army, Lanzhou 730050, Gansu Province, China

Jian-Guo Ma, First School of Clinical Medicine, Gansu University of Chinese Medicine, Lanzhou 730030, Gansu Province, China

Co-first authors: Xiao-Yu Du and Ren-Jie Xia.

Co-corresponding authors: Shu-Mei Xu and Long Yan.

Author contributions: Du XY, Xia RJ and Shen LW contributed equally to this work; Xu SM and Yan L contributed equally to this work as co-corresponding authors; Du XY was responsible for drafting of the manuscript; Xu SM and Yan L were responsible for planning treatment decisions; Xia RJ, Shen LW and Ma JG were responsible for evaluating imaging outcome; Du XY and Xia RJ were listed as co-first authors; Yao WQ and Xu W were responsible for pathological interpretation; Du XY, Xia RJ, Shen LW, Ma JG, Xu W, Lin ZP, Ma LB, Niu GQ, Fan RF, Xu SM and Yan L were responsible for clinical data analysis and taking care of the patient; all authors contributed to the article and approved the submitted version.

Supported by the Health Industry Research Program of Gansu Province, No. GSWSKY2021-043; the Youth Science and Technology Foundation of Gansu Province, No. 22JR11RA002; and the Natural Science Foundation of Gansu Province, No. 22JR5RA008.

Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.

Conflict-of-interest statement: The authors declare that they have no conflict of interest.

CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Long Yan, MD, Associate Chief Physician, Department of Hepatobiliary Surgery and General Surgery, The 940^th Hospital of Joint Logistic Support Force of Chinese People’s Liberation Army, No. 333 Nanbinhe Middle Road, Qilihe District, Lanzhou 730050, Gansu Province, China. lzzy940@163.com

Received: October 13, 2024
Revised: January 20, 2025
Accepted: February 24, 2025
Published online: April 15, 2025
Processing time: 163 Days and 8.4 Hours

Core Tip

Core Tip: The prognosis for patients with unresectable or metastatic gastric cancer remains poor. The efficacy and safety of chemotherapy and immunotherapy require further improvement. We have designed an innovative first-line quadruple conversion therapy regimen that integrates a programmed cell death protein 1 inhibitor with chemotherapy, successfully implemented in the treatment of a patient with unresectable locally advanced gastric adenocarcinoma.